| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière, Paris, France.
Address correspondence and reprint requests to Dr. Y. Agid, Fédération de Neurologie and INSERM U289, Hôpital de la Salpetrière, 47 Boulevard de l'Hôpital, 75651 Paris, Cedex, France.
Whether a drug such as levodopa, which is prescribed for long periods, may be toxic is a legitimate and even indispensable question. The problem is no different from that posed by other drugs-such as calcium antagonists, antihypertensives, or hormones-normally prescribed for chronic diseases. What, however, is meant in this context by "toxic" (from the Greek toxicon, meaning poison)? Irrevocable damage such as cell loss should not be confused with reversible side effects resulting from cell dysfunction. Clinically or experimentally, levodopa has not been shown to accelerate neurodegeneration or cause permanent impairment of cell function in a manner that would result in irreversible side effects. These data have been reasonably well established in vivo in animals and humans, although preliminary studies suggesting that levodopa is a trophic factor remain unconfirmed. Like oxygen or calcium, levodopa can be toxic in vitro when it is present in high concentrations or in the absence of glial cells. However, glial cells are much more numerous than neurons in vivo, so these conditions cannot simply be extrapolated to three-dimensional brain structures in which protective interactions with the cellular environment abound. Because levodopa remains the most effective treatment available for Parkinson's disease, questions regarding timing or manner of administration of the drug should arise not because levodopa is toxic to nerve cells, but because it causes reversible side effects. When the elementary rules of substitutive therapy to provide maximum comfort while limiting side effects are followed, we need not fear that levodopa is dangerous unless the contrary is proven.
Received September 12, 1997. Accepted in final form November 25, 1997.
This article has been cited by other articles:
|
|
 |
|
  The Parkinson Study Group Levodopa and the Progression of Parkinson's Disease N. Engl. J. Med., December 9, 2004; 351(24): 2498 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Weiner Initial Treatment of Parkinson Disease: Levodopa or Dopamine Agonists Arch Neurol, December 1, 2004; 61(12): 1966 - 1969. [Full Text] [PDF]
|
|
|
|
|
|
T. Muller, K. Renger, and W. Kuhn Levodopa-Associated Increase of Homocysteine Levels and Sural Axonal Neurodegeneration Arch Neurol, May 1, 2004; 61(5): 657 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Koller and W. Tse Unmet medical needs in Parkinson's disease Neurology, January 13, 2004; 62(90011): S1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Albin and K. A. Frey Initial agonist treatment of Parkinson disease: A critique Neurology, February 11, 2003; 60(3): 390 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.E. Lang, G. Kleiner-Fisman, J.A. Saint-Cyr, J. Miyasaki, A. Lozano, J.L. Houeto, V. Mesnage, M.L. Welter, L. Mallet, Y. Agid, et al. Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up Neurology, January 14, 2003; 60(1): 154 - 155. [Full Text] [PDF]
|
|
|
|
|
|
G. Kleiner-Fisman, J.A. Saint-Cyr, J. Miyasaki, A. Lozano, A.E. Lang, F.J. G. Vingerhoets, J.G. Villemure, and J. Ghika Subthalamic DBS replaces levodopa in Parkinson's disease Neurology, October 22, 2002; 59(8): 1293 - 1294. [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. A. Conway, J.-C. Rochet, R. M. Bieganski, and P. T. Lansbury Jr. Kinetic Stabilization of the alpha -Synuclein Protofibril by a Dopamine-alpha -Synuclein Adduct Science, November 9, 2001; 294(5545): 1346 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Münchau and K P Bhatia Pharmacological treatment of Parkinson's disease Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610. [Full Text]
|
|
|
|
|
|
W. J. Weiner Is Levodopa Toxic? Arch Neurol, March 1, 2000; 57(3): 408 - 410. [Full Text] [PDF]
|
|
|
|
|
|
K. Kompoliti, Q. E. Wang, C. G. Goetz, S. Leurgans, and R. Raman Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease Neurology, January 25, 2000; 54(2): 458 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic New and Emerging Therapies for Parkinson Disease Arch Neurol, July 1, 1999; 56(7): 785 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fahn Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial Arch Neurol, May 1, 1999; 56(5): 529 - 535. [Full Text] [PDF]
|
|
|
|
|
|
A. E. Lang and A. M. Lozano Parkinson's Disease- Second of Two Parts N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
